<DOC>
	<DOCNO>NCT01791231</DOCNO>
	<brief_summary>The purpose study investigate absorption ( way drug enters body ) , metabolism ( way drug broken body ) , excretion ( way drug leave body ) canagliflozin ( JNJ-28431754 ) healthy male volunteer single dose radiolabeled 14C-canagliflozin ( 14C-JNJ-28431754 ) . The safety tolerability canagliflozin also assess .</brief_summary>
	<brief_title>A Study Investigate Absorption , Metabolism , Excretion Canagliflozin ( JNJ-28431754 ) Healthy Male Volunteers</brief_title>
	<detailed_description>This study open label ( volunteer study staff know identity assign treatment ) , single dose , single center study investigate absorption , metabolism , excretion canagliflozin ( drug currently investigate treatment type 2 diabetes mellitus ) . The study consist 3 phase : screening phase , open-label treatment phase , end-of study ( follow-up ) phase . On Day 1 , volunteer receive single oral dose radiolabeled 14C-canagliflozin contains 196 mg canagliflozin approximately 40 microcurie ( 1480kBq ) radioactivity . The International Commission Radiological Protection considers amount radioactivity acceptable type study . The radioactivity allow amount canagliflozin metabolite ( break-down product ) precisely measure blood , plasma , urine , feces sample , collect volunteer . The total duration study approximately 5 week ( include screen follow-up ) ; time increase 6 day volunteer slower rate excretion canagliflozin .</detailed_description>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Body Mass Index ( BMI ) ( weight [ kg ] /height [ m2 ] ) 18 30 kg/m2 Nonsmoker Exposure radiation professional medical reason ( except dental xrays xrays thorax bone skeleton , exclude spinal column ) past 12 month History currently active illness consider clinically significant Investigator illness Investigator considers exclude patient study could interfere interpretation study result</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Male</keyword>
	<keyword>Canagliflozin ( JNJ-28431754 )</keyword>
	<keyword>Radiolabeled 14C-canagliflozin</keyword>
	<keyword>Absorption</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Excretion</keyword>
	<keyword>Radioactivity</keyword>
</DOC>